Oct 04, 2022 8:45am EDT Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
Sep 09, 2022 8:00am EDT Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
Aug 24, 2022 8:00am EDT Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
Aug 05, 2022 7:00am EDT Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
Jun 08, 2022 7:00am EDT Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
Jun 06, 2022 4:47pm EDT Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
May 23, 2022 4:05pm EDT Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th